WI Harper Group-backed XWPharma Initiates First-in-Human Studies of Treatment-Resistant Depression and Chronic Pain Therapy
[vc_row][vc_column][vc_column_text] WI Harper Group | September 13, 2021 | Source: XWPharma WWI Harper-backed XWPharma, a biopharmaceutical company dedicated to the discovery and development of therapeutics, announced its first-in-human study evaluating XW10508 – the Company’s novel, patented, glutamatergic NMDA antagonist and…